With Next Gen Sequencing (NGS) being one of the widely applied cross-omics application, the industry majorly covers the Services and Technologies from the Life Science and Healthcare Vertical, with a diseased condition or specific therapeutic areas.  

The major technologies in the NGS being Sequencing by synthesis (SBS), Ion semiconductor sequencing, Single Molecule, Real-Time (SMRT) sequencing and Nanopore sequencing. The Product portfolio covers Sequencing Platforms, Assay Designing and the Data Analysis Services, while the Application side delivers into Diagnostics, Drug Discovery and Development, Personalized Medicine and Pre-Natal and Reproductive health. The major disease area include Oncology, Infectious Diseases, Idiopathic Diseases and Immune and Metabolic System Monitoring.

With FDA’s approval for NGS Diagnostics for Covid-19, the diagnostic application in the cross-omics industry is expected to expand more than previously predicted, leading to more collaborations. The use of gene sequenced data in the clinical trials has seen an increase and this will add value to the NGS market. The active and keep innovating attitude of the Key players and Big Healthcare, such as Illumina, Inc., Admera Health, Applied Biological Materials, BGI Group, CD Genomics, DNA Link, Eurofins Genomics (Eurofins Scientific), Fulgent Genetics, Gene By Gene, GENEWIZ, MedGenome, Novogene, Omega Biosciences, Psomagen, Veritas Genetics, Xcerlis Labs, Oxford Nanopore Technologies, Thermo Fisher Scientific, and more has given the necessary boost.

In addition to Price competitive, the expanding market space of Genomics and NGS have to be understood from the Ethical and Regulatory perspective, and there is a lot more scope and work to be done in that area.